|Classification and external resources|
Stomach cancer or gastric cancer, is when cancer develops from the lining of the stomach. Early symptoms may include: heartburn, upper abdominal pain, nausea and loss of appetite. Later symptoms may include: weight loss, yellow skin, vomiting, difficulty swallowing and blood in the stool among others. The cancer may spread from the stomach to other parts of the body, particularly the liver, lungs, bones, lining of the abdomen and lymph nodes.
The most common cause is infection by the bacteria Helicobacter pylori, which accounts for more than 60% of cases. Certain type of H. pylori have greater risks than others. Other common causes include eating pickled vegetables and smoking. About 10% of cases run in families and between 1% and 3% of cases are due to genetic syndromes inherited from a person's parents such as hereditary diffuse gastric cancer. Most cases of stomach cancers are gastric carcinomas. This type can be divided into a number of subtypes. Lymphomas and mesenchymal tumors may also develop within the stomach. Most of the time, stomach cancer develops through a number of stages over a number of years. Diagnosis is usually by biopsy done during endoscopy. This is then followed by medical imaging to determine if the disease has spread to other parts of the body. Japan and South Korea, two countries that have high rates of disease, screen for stomach cancer.
A Mediterranean diet lowers the risk of cancer as does the stopping of smoking. There is tentative evidence that treating H. pylori decreases the future risk. If cancer is treated early many cases can be cured. Treatments may include some combination of: surgery, chemotherapy, radiation therapy and targeted therapy. If treated late palliative care may be advised. Outcomes are often poor with a less than 10% 5-year survival rate globally. This is largely because most people with the condition present with advanced disease. In the United States 5-year survival is 28% while in South Korea it is over 65% partly due to screening efforts.
Globally stomach cancer is the fifth leading cause of cancer and the third leading cause of death from cancer making up 7% of cases and 9% of deaths. In 2012 it occurred in 950,000 people and caused 723,000 deaths. Before the 1930s in much of the world, including the United States and the United Kingdom, it was the most common cause of death from cancer. Rates of death have been decreasing in many areas of the world since then. This is believed to be due to the eating of less salted and pickled foods as a result of the development of refrigeration as a method of keeping food fresh. Stomach cancer occurs most commonly in East Asia and Eastern Europe and it occurs twice as often in males as in females.
Signs and symptoms
Stomach cancer is often either asymptomatic (producing no noticeable symptoms) or it may cause only nonspecific symptoms (symptoms that are specific not only to stomach cancer, but also to other related or unrelated disorders) in its early stages. By the time symptoms occur, the cancer has often reached an advanced stage (see below) and may have also metastasized (spread to other, perhaps distant, parts of the body), which is one of the main reasons for its relatively poor prognosis. Stomach cancer can cause the following signs and symptoms:
Early cancers may be associated with indigestion or a burning sensation (heartburn). However, less than 1 in every 50 people referred for endoscopy due to indigestion has cancer. Abdominal discomfort and loss of appetite, especially for meat, can occur.
Gastric cancers that have enlarged and invaded normal tissue can cause weakness, fatigue, bloating of the stomach after meals, abdominal pain in the upper abdomen, nausea and occasional vomiting, diarrhea or constipation. Further enlargement may cause weight loss or bleeding with vomiting blood or having blood in the stool, the latter apparent as black discolouration (melena) and sometimes leading to anemia. Dysphagia suggests a tumour in the cardia or extension of the gastric tumour into the esophagus.
Gastric cancer is a multifactorial disease. Helicobacter pylori infection is an essential risk factor in 65–80% of gastric cancers, but in only 2% of such infections. The mechanism by which H. pylori induces stomach cancer potentially involves chronic inflammation, or the action of H. pylori virulence factors such as CagA.
Smoking increases the risk of developing gastric cancer significantly, from 40% increased risk for current smokers to 82% increase for heavy smokers. Gastric cancers due to smoking mostly occur in the upper part of the stomach near the esophagus. Some studies show increased risk with alcohol consumption as well.
Dietary factors are not proven causes, but some foods including smoked foods, salt and salt-rich foods, red meat, processed meat, pickled vegetables, and bracken are associated with a higher risk of stomach cancer. Nitrates and nitrites in cured meats can be converted by certain bacteria, including H. pylori, into compounds that have been found to cause stomach cancer in animals. On the other hand, fresh fruit and vegetable intake, citrus fruit intake, and antioxidant intake are associated with a lower risk of stomach cancer. A Mediterranean diet is also associated with lower rates of stomach cancer, as is regular aspirin use.
Approximately 10% of cases show a genetic component.
People may possess certain risk factors, such as those that are physical or genetic, that can alter their susceptibility for gastric cancer. Obesity is one such physical risk factor that has been found to increase the risk of gastric adenocarcinoma by contributing to the development of gastroesphageal reflux disease (GERD).The exact mechanism by which obesity causes GERD is not completely known. Studies hypothesize that increased dietary fat leading to increased pressure on the stomach and the lower esophageal sphincter, due to excess adipose tissue, could play a role, yet no statistically significant data has been collected. However, the risk of gastric cardia adenocarcinoma, with GERD present, has been found to increase more than 2 times for an obese person. A genetic risk factor for gastric cancer is a genetic defect of the CDH1 gene known as hereditary diffuse gastric cancer (HDGC). The CDH1 gene, which codes for E-cadherin, lies on the 16th chromosome.When the gene experiences a particular mutation, gastric cancer develops through a mechanism that is not fully understood.This mutation is considered autosomal dominant meaning that half of a carrier’s children will likely experience the same mutation.Diagnosis of hereditary diffuse gastric cancer usually takes place when at least two cases involving a family member, such as a parent or grandparent, are diagnosed, with at least one diagnosed before the age of 50.The diagnosis can also be made if there are at least three cases in the family, in which case age is not considered.
The International Cancer Genome Consortium is leading efforts to identify genomic changes involved in stomach cancer. A very small percentage of diffuse-type gastric cancers (see Histopathology below) arise from an inherited abnormal CDH1 gene. Genetic testing and treatment options are available for families at risk.
Other factors associated with increased risk are AIDS, diabetes, pernicious anaemia, chronic atrophic gastritis, Menetrier's disease (hyperplastic, hypersecretory gastropathy), and intestinal metaplasia.
To find the cause of symptoms, the doctor asks about the patient's medical history, does a physical exam, and may order laboratory studies. The patient may also have one or all of the following exams:
- Gastroscopic exam is the diagnostic method of choice. This involves insertion of a fibre optic camera into the stomach to visualise it.
- Upper GI series (may be called barium roentgenogram).
- Computed tomography or CT scanning of the abdomen may reveal gastric cancer, but is more useful to determine invasion into adjacent tissues, or the presence of spread to local lymph nodes. Wall thickening of more than 1 cm that is focal, eccentric and enhancing favours malignancy.
In 2013, Chinese and Israeli scientists reported a successful pilot study of a breathalyzer-style breath test intended to diagnose stomach cancer by analyzing exhaled chemicals without the need for an intrusive endoscopy. A larger-scale clinical trial is now underway.
Abnormal tissue seen in a gastroscope examination will be biopsied by the surgeon or gastroenterologist. This tissue is then sent to a pathologist for histological examination under a microscope to check for the presence of cancerous cells. A biopsy, with subsequent histological analysis, is the only sure way to confirm the presence of cancer cells.
Various gastroscopic modalities have been developed to increase yield of detected mucosa with a dye that accentuates the cell structure and can identify areas of dysplasia. Endocytoscopy involves ultra-high magnification to visualise cellular structure to better determine areas of dysplasia. Other gastroscopic modalities such as optical coherence tomography are also being tested investigationally for similar applications.
A number of cutaneous conditions are associated with gastric cancer. A condition of darkened hyperplasia of the skin, frequently of the axilla and groin, known as acanthosis nigricans, is associated with intra-abdominal cancers such as gastric cancer. Other cutaneous manifestations of gastric cancer include tripe palms (a similar darkening hyperplasia of the skin of the palms) and the Leser-Trelat sign, which is the rapid development of skin lesions known as seborrheic keratoses.
- Gastric adenocarcinoma is a malignant epithelial tumour, originating from glandular epithelium of the gastric mucosa. Stomach cancers are overwhelmingly adenocarcinomas (90%). Histologically, there are two major types of gastric adenocarcinoma (Lauren classification): intestinal type or diffuse type. Adenocarcinomas tend to aggressively invade the gastric wall, infiltrating the muscularis mucosae, the submucosa and thence the muscularis propria. Intestinal type adenocarcinoma tumour cells describe irregular tubular structures, harbouring pluristratification, multiple lumens, reduced stroma ("back to back" aspect). Often, it associates intestinal metaplasia in neighbouring mucosa. Depending on glandular architecture, cellular pleomorphism and mucosecretion, adenocarcinoma may present 3 degrees of differentiation: well, moderate and poorly differentiated. Diffuse type adenocarcinoma (mucinous, colloid, linitis plastica, leather-bottle stomach) tumour cells are discohesive and secrete mucus, which is delivered in the interstitium, producing large pools of mucus/colloid (optically "empty" spaces). It is poorly differentiated. If the mucus remains inside the tumour cell, it pushes the nucleus to the periphery: "signet-ring cell".
- Around 5% of gastric malignancies are lymphomas (MALTomas, or MALT lymphoma).
- Carcinoid and stromal tumors may also occur.
If cancer cells are found in the tissue sample, the next step is to stage, or find out the extent of the disease. Various tests determine whether the cancer has spread and, if so, what parts of the body are affected. Because stomach cancer can spread to the liver, the pancreas, and other organs near the stomach as well as to the lungs, the doctor may order a CT scan, a PET scan, an endoscopic ultrasound exam, or other tests to check these areas. Blood tests for tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) may be ordered, as their levels correlate to extent of metastasis, especially to the liver, and the cure rate.
Staging may not be complete until after surgery. The surgeon removes nearby lymph nodes and possibly samples of tissue from other areas in the abdomen for examination by a pathologist.
- Stage 0. Limited to the inner lining of the stomach. Treatable by endoscopic mucosal resection when found very early (in routine screenings); otherwise by gastrectomy and lymphadenectomy without need for chemotherapy or radiation.
- Stage I. Penetration to the second or third layers of the stomach (Stage 1A) or to the second layer and nearby lymph nodes (Stage 1B). Stage 1A is treated by surgery, including removal of the omentum. Stage 1B may be treated with chemotherapy (5-fluorouracil) and radiation therapy.
- Stage II. Penetration to the second layer and more distant lymph nodes, or the third layer and only nearby lymph nodes, or all four layers but not the lymph nodes. Treated as for Stage I, sometimes with additional neoadjuvant chemotherapy.
- Stage III. Penetration to the third layer and more distant lymph nodes, or penetration to the fourth layer and either nearby tissues or nearby or more distant lymph nodes. Treated as for Stage II; a cure is still possible in some cases.
- Stage IV. Cancer has spread to nearby tissues and more distant lymph nodes, or has metastatized to other organs. A cure is very rarely possible at this stage. Some other techniques to prolong life or improve symptoms are used, including laser treatment, surgery, and/or stents to keep the digestive tract open, and chemotherapy by drugs such as 5-fluorouracil, cisplatin, epirubicin, etoposide, docetaxel, oxaliplatin, capecitabine or irinotecan.
In a study of open-access endoscopy in Scotland, patients were diagnosed 7% in Stage I 17% in Stage II, and 28% in Stage III. A Minnesota population was diagnosed 10% in Stage I, 13% in Stage II, and 18% in Stage III. However in a high-risk population in the Valdivia Province of southern Chile, only 5% of patients were diagnosed in the first two stages and 10% in stage III.
Cancer of the stomach is difficult to cure unless it is found at an early stage (before it has begun to spread). Unfortunately, because early stomach cancer causes few symptoms, the disease is usually advanced when the diagnosis is made. Treatment for stomach cancer may include surgery, chemotherapy, and/or radiation therapy. New treatment approaches such as biological therapy and improved ways of using current methods are being studied in clinical trials.
Surgery remains the only curative therapy for stomach cancer. Of the different surgical techniques, endoscopic mucosal resection (EMR) is a treatment for early gastric cancer (tumor only involves the mucosa) that has been pioneered in Japan, but is also available in the United States at some centers. In this procedure, the tumor, together with the inner lining of stomach (mucosa), is removed from the wall of the stomach using an electrical wire loop through the endoscope. The advantage is that it is a much smaller operation than removing the stomach. Endoscopic submucosal dissection (ESD) is a similar technique pioneered in Japan, used to resect a large area of mucosa in one piece. If the pathologic examination of the resected specimen shows incomplete resection or deep invasion by tumor, the patient would need a formal stomach resection.
Those with metastatic disease at the time of presentation may receive palliative surgery and while it remains controversial, due to the possibility of complications from the surgery itself and the fact that it may delay chemotherapy the data so far is mostly positive, with improved survival rates being seen in those treated with this approach.
The use of chemotherapy to treat stomach cancer has no firmly established standard of care. Unfortunately, stomach cancer has not been particularly sensitive to these drugs, and chemotherapy, if used, has usually served to palliatively reduce the size of the tumor, relieve symptoms of the disease and increase survival time. Some drugs used in stomach cancer treatment have included: 5-FU (fluorouracil) or its analog capecitabine, BCNU (carmustine), methyl-CCNU (semustine) and doxorubicin (Adriamycin), as well as mitomycin C, and more recently cisplatin and taxotere, often using drugs in various combinations. The relative benefits of these different drugs, alone and in combination, are unclear. Clinical researchers have explored the benefits of giving chemotherapy before surgery to shrink the tumor, or as adjuvant therapy after surgery to destroy remaining cancer cells. Recently, a targeted treatment called trastuzumab has become available for use with chemotherapy for the treatment of those overexpressing the HER2 gene in their tumor cells.
The prognosis of stomach cancer is generally poor, due to the fact the tumour has often metastasised by the time of discovery and the fact that most people with the condition are elderly (median age is between 70 and 75 years) at presentation. The 5-year survival rate for stomach cancer is reported to be less than 10%.
Stomach cancer is the fourth most common cancer worldwide with 930,000 cases diagnosed in 2002. It is more common in men and in developing countries. In 2012, it represented 8.5% of cancer cases in men, making it the fourth most common cancer in men. In 2012 number of deaths were 700,000 having decreased slightly from 774,000 in 1990 making it the third leading cause of cancer death after lung cancer and liver cancer.
Less than 5% of stomach cancers occur in people under 40 years of age with 81.1% of that 5% in the age-group of 30 to 39 and 18.9% in the age-group of 20 to 29.
In 2011, stomach cancer accounted for 0.64% of deaths (13,230 cases) in the United States. In China, stomach cancer accounted for 3.99% of all deaths (354,829 cases). The mortality rate was highest in the Maldives, stomach cancer accounting for 8.92% of all deaths.
Stomach cancer is the fifteenth most common cancer in the UK (around 7,100 people were diagnosed with stomach cancer in 2011), and it is the tenth most common cause of cancer death (around 4,800 people died in 2012).
Incidence and mortality rates of gastric cancer vary greatly in Africa. The GLOBOCAN system is currently the most widely used method to compare these rates between countries, but African incidence and mortality rates are seen to differ among countries possibly due to the lack of universal access to a registry system for all countries. Variation as drastic as estimated rates from 0.3/100000 in Mali to 20.3/100000 in Botswana have been observed. In Uganda, the incidence of gastric cancer has increased from the 1960s measurement of 0.8/100000 to 5.6/100000. Gastric cancer, though present, is relatively low when compared to countries with high incidence like Japan or China. One suspected cause of the variation within Africa and between other countries is due to different strains of the Helicobacter pylori bacteria. The trend commonly seen is that H. pylori infection increases the risk for gastric cancer, however this is not the case in Africa giving this phenomenon the name the “African enigma.” Although this bacteria is found in Africa, evidence has supported that different strains with mutations in the bacterial genotype may contribute to the difference in cancer development between African countries and others outside of the continent. But, increasing access to health care and treatment measures have been commonly associated with the rising incidence, particularly in Uganda. 
The stomach is a muscular organ of the gastrointestinal tract that holds food and begins the digestive process by secreting gastric juice. The most common cancers of the stomach are adenocarcinomas but other histological types have been reported. Signs vary but may include vomiting (especially if blood is present), weight loss, anemia, and lack of appetite. Bowel movements may be dark and tarry in nature. In order to determine whether cancer is present in the stomach, special X-rays and/or abdominal ultrasound may be performed. Gastroscopy, a test using an instrument called endoscope to examine the stomach, is a useful diagnostic tool that can also take samples of the suspected mass for histopathological analysis to confirm or rule out cancer. The most definitive method of cancer diagnosis is through open surgical biopsy. Most stomach tumors are malignant with evidence of spread to lymph nodes or liver, making treatment difficult. Except for lymphoma, surgery is the most frequent treatment option for stomach cancers but it is associated with significant risks.
- "Stomach (Gastric) Cancer". NCI. Retrieved 1 July 2014.
- "Gastric Cancer Treatment (PDQ®)". NCI. 2014-04-17. Retrieved 1 July 2014.
- Ruddon, Raymond W. (2007). Cancer biology (4th ed.). Oxford: Oxford University Press. p. 223. ISBN 9780195175431.
- Sim, edited by Fiona; McKee, Martin (2011). Issues in public health (2nd ed.). Maidenhead: Open University Press. p. 74. ISBN 9780335244225.
- World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.4. ISBN 9283204298.
- "Stomach (Gastric) Cancer Prevention (PDQ®)". NCI. 2014-02-27. Retrieved 1 July 2014.
- Orditura, M; Galizia, G; Sforza, V; Gambardella, V; Fabozzi, A; Laterza, MM; Andreozzi, F; Ventriglia, J; Savastano, B; Mabilia, A; Lieto, E; Ciardiello, F; De Vita, F (February 2014). "Treatment of gastric cancer." (PDF). World Journal of Gastroenterology 20 (7): 1635–49. doi:10.3748/wjg.v20.i7.1635. PMC 3930964. PMID 24587643.
- "SEER Stat Fact Sheets: Stomach Cancer". NCI. Retrieved 18 June 2014.
- "Chapter 1.1". World Cancer Report 2014. World Health Organization. 2014. ISBN 9283204298.
- Hochhauser, Jeffrey Tobias, Daniel (2010). Cancer and its management (6th ed.). Chichester, West Sussex, UK: Wiley-Blackwell. p. 259. ISBN 9781444306378.
- Khleif, Edited by Roland T. Skeel, Samir N. (2011). Handbook of cancer chemotherapy (8th ed.). Philadelphia: Wolter Kluwer. p. 127. ISBN 9781608317820.
- Joseph A Knight (2010). Human Longevity: The Major Determining Factors. Author House. p. 339. ISBN 9781452067223.
- Moore, edited by Rhonda J.; Spiegel, David (2004). Cancer, culture, and communication. New York: Kluwer Academic. p. 139. ISBN 9780306478857.
- "Statistics and outlook for stomach cancer". Cancer Research UK. Retrieved 19 February 2014.
- "Guidance on Commissioning Cancer Services Improving Outcomes in Upper Gastro-intestinal Cancers". NHS. Jan 2001.
- Lee YY, Derakhshan MH (Jun 2013). "Environmental and lifestyle risk factors of gastric cancer". Arch Iran Med. 16 (6): 358–65. PMID 23725070.
- "Proceedings of the fourth Global Vaccine Research Forum". Initiative for Vaccine Research team of the Department of Immunization, Vaccines and Biologicals. WHO. April 2004. Retrieved 2009-05-11.
Epidemiology of Helicobacter pylori and gastric cancer…
- González CA, Sala N, Rokkas T; Sala; Rokkas (2013). "Gastric cancer: epidemiologic aspects". Helicobacter 18 (Supplement 1): 34–38. doi:10.1111/hel.12082. PMID 24011243.
- Hatakeyama, M. & Higashi, H; Higashi (2005). "Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis". Cancer Science 96 (12): 835–843. doi:10.1111/j.1349-7006.2005.00130.x. PMID 16367902.
- "What Are The Risk Factors For Stomach Cancer(Website)". American Cancer Society. Retrieved 2010-03-31.
- Nomura A, Grove JS, Stemmermann GN, Severson RK; Grove; Stemmermann; Severson (1990). "Cigarette smoking and stomach cancer". Cancer Research 50 (21): 7084. PMID 2208177.
- Trédaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A; Boffetta; Buiatti; Saracci; Hirsch (August 1997). "Tobacco smoking and gastric cancer: Review and meta-analysis". International Journal of Cancer 72 (4): 565–73. doi:10.1002/(SICI)1097-0215(19970807)72:4<565::AID-IJC3>3.0.CO;2-O. PMID 9259392.
- Thrumurthy SG, Chaudry MA, Hochhauser D, Ferrier K, Mughal M; Chaudry; Hochhauser; Mughal (2013). "The diagnosis and management of gastric cancer". British Medical Journal 347 (16): 1695–6. doi:10.1136/bmj.f6367. PMID 24291271.
- Tumors of the GI Tract at Merck Manual of Diagnosis and Therapy Professional Edition
- Jakszyn P, González CA; Gonzalez (2006). "Nitrosamine and related food intake and gastric and oesophageal cancer risk: A systematic review of the epidemiological evidence". World J Gastroenterol 12 (27): 4296–4303. PMC 4087738. PMID 16865769.
- Alonso-Amelot ME, Avendaño M; Avendaño (March 2002). "Human carcinogenesis and bracken fern: a review of the evidence". Current Medicinal Chemistry 9 (6): 675–86. doi:10.2174/0929867023370743. PMID 11945131.
- Buckland G, Agudo A, Lujan L, Jakszyn P, Bueno-De-Mesquita HB, Palli D, Boeing H, Carneiro F, Krogh V; Agudo; Luján; Jakszyn; Bueno-De-Mesquita; Palli; Boeing; Carneiro; Krogh; Sacerdote; Tumino; Panico; Nesi; Manjer; Regnér; Johansson; Stenling; Sanchez; Dorronsoro; Barricarte; Navarro; Quirós; Allen; Key; Bingham; Kaaks; Overvad; Jensen; Olsen et al. (2009). "Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study". American Journal of Clinical Nutrition 91 (2): 381–90. doi:10.3945/ajcn.2009.28209. PMID 20007304.
- Josefssson, M.; Ekblad, E. (2009). "22. Sodium Iodide Symporter (NIS) in Gastric Mucosa: Gastric Iodide Secretion". In Preedy, Victor R.; Burrow, Gerard N.; Watson, Ronald. Comprehensive Handbook of Iodine: Nutritional, Biochemical, Pathological and Therapeutic Aspects. Elsevier. pp. 215–220. ISBN 978-0-12-374135-6.
- Venturi, Sebastiano (2011). "Evolutionary Significance of Iodine". Current Chemical Biology- 5 (3): 155–162. doi:10.2174/187231311796765012. ISSN 1872-3136.
- Venturi II, S.; Donati, F.M.; Venturi, A.; Venturi, M.;; Venturi, A; Venturi, M; Grossi, L; Guidi, A (2000). "Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach.". Adv Clin Path 4 (1): 11–17. PMID 10936894.
- Venturi, S.; Donati, F.M.; Venturi, A.; Venturi, M. (2000). "Environmental Iodine Deficiency: A Challenge to the Evolution of Terrestrial Life?". Thyroid 10 (8): 727–9. doi:10.1089/10507250050137851. PMID 11014322.
- Chandanos, Evangelos (December 2007). Estrogen in the development of esophageal and gastric adenocarcinoma (PDF) (Doctoral thesis). Karolinska Institutet. ISBN 978-91-7357-370-2.
- Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 2008 Nov;44(16):2397-403.
- Qin J, Liu M, Ding Q, Ji X, Hao Y, Wu X, Xiong J. The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells. Mol Cell Biochem. 2014 Oct;395(1-2):99-107.
- Lee H-J, Yang H-K, Ahn Y-O; Yang; Ahn (2002). "Gastric cancer in Korea". Gastric Cancer 5 (3): 177–82. doi:10.1007/s101200200031. PMID 12378346.
- Crew K, Neugut A (January 2006). "Epidemiology of gastric cancer". World Journal of Gastroenterology 12 (3): 354–62.
- Hampel Howard, Abraham Neena S., and El-Serag Hashem B. (August 2005). "Meta-Analysis: obesity and the risk for gastroesophageal reflux disease and its complications". Annal of Internal Medicine 143 (3): 199–211.
- "Hereditary Diffuse Cancer". No Stomach for Cancer. Retrieved 21 Oct 2014.
- "Gastric Cancer — Adenocarcinoma". International Cancer Genome Consortium. Retrieved 24 February 2014.
- "Gastric Cancer — Intestinal- and diffuse-type". International Cancer Genome Consortium. Retrieved 24 February 2014.
- Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J; Kaurah; Suriano; Leach; Senz; Grehan; Butterfield; Jeyes; Schinas; Bacani; Kelsey; Ferreira; MacGillivray; MacLeod; Micek; Ford; Foulkes; Australie; Greenberg; Lapointe; Gilpin; Nikkel; Gilchrist; Hughes; Jackson; Monaghan; Oliveira; Seruca; Gallinger et al. (2004). "Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria". Journal of Medical Genetics 41 (7): 508–17. doi:10.1136/jmg.2004.018275. PMC 1735838. PMID 15235021.
- Tseng C-H, Tseng F-H; Tseng (2014). "Diabetes and gastric cancer: The potential links". World J Gastroenterol 20 (7): 1701–11. doi:10.3748/wjg.v20.i7.1701. PMC 3930970. PMID 24587649.
- Crosby DA, Donohoe CL, Fitzgerald L, Muldoon C, Hayes B, O’Toole D, Reynolds JV; Donohoe; Fitzgerald; Muldoon; Hayes; O'Toole; Reynolds (2004). "Gastric Neuroendocrine Tumours". Digestive Surgery 29 (4): 331–348. doi:10.1159/000342988. PMID 23075625.
- Kim J, Cheong JH, Chen J, Hyung WJ, Choi SH, Noh SH; Cheong; Chen; Hyung; Choi; Noh (2004). "Menetrier's Disease in Korea: Report of Two Cases and Review of Cases in a Gastric Cancer Prevalent Region". Yonsei Medical Journal 45 (3): 555–560. PMID 15227748.
- Tsukamoto T, Mizoshita T, Tatematsu M; Mizoshita; Tatematsu (2006). "Gastric-and-intestinal mixed-type intestinal metaplasia: aberrant expression of transcription factors and stem cell intestinalization". Gastric cancer 9 (3): 156–166. doi:10.1007/s10120-006-0375-6. PMID 16952033.
- Virmani, V; Khandelwal, A; Sethi, V; Fraser-Hill, M; Fasih, N; Kielar, A (2012). "Neoplastic stomach lesions and their mimickers: Spectrum of imaging manifestations". Cancer imaging : the official publication of the International Cancer Imaging Society 12: 269–78. doi:10.1102/1470-7330.2012.0031. PMC 3458788. PMID 22935192.
- Xu ZQ, Broza YY, Ionsecu R et al. (March 2013). "A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions". Br. J. Cancer 108 (4): 941–50. doi:10.1038/bjc.2013.44. PMC 3590679. PMID 23462808. [Breath Test Could Detect And Diagnose Stomach Cancer Lay summary] – Medical News Today (6 March 2013).
- Inoue H, Kudo S-, Shiokawa A; Kudo; Shiokawa (2005). "Technology Insight: laser-scanning confocal microscopy and endocytoscopy for cellular observation of the gastrointestinal tract". Nature Clinical Practice Gastroenterology & Hepatology 2 (1): 31–7. doi:10.1038/ncpgasthep0072. PMID 16265098.
- Pentenero M, Carrozzo M, Pagano M, Gandolfo S; Carrozzo; Pagano; Gandolfo (2004). "Oral acanthosis nigricans, tripe palms and sign of leser-trelat in a patient with gastric adenocarcinoma". International Journal of Dermatology 43 (7): 530–2. doi:10.1111/j.1365-4632.2004.02159.x. PMID 15230897.
- Kumar; et al. (2010). Pathologic Basis of Disease (8th ed.). Saunders Elsevier. p. 784. ISBN 978-1-4160-3121-5.
- Kumar 2010, p. 786
- Lim JS, Yun MJ, Kim MJ, Hyung WJ, Park MS, Choi JY, Kim TS, Lee JD, Noh SH, Kim KW; Yun; Kim; Hyung; Park; Choi; Kim; Lee; Noh; Kim (2006). "CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy". Radiographics 26 (1): 143–156. doi:10.1148/rg.261055078. PMID 16418249.
- "Detailed Guide: Stomach Cancer Treatment Choices by Type and Stage of Stomach Cancer". American Cancer Society. 2009-11-03.
- Guy Slowik (October 2009). "What Are The Stages Of Stomach Cancer?". ehealthmd.com.
- "Detailed Guide: Stomach Cancer: How Is Stomach Cancer Staged?". American Cancer Society.
- Paterson HM, McCole D, Auld CD; McCole; Auld (2006). "Impact of open-access endoscopy on detection of early oesophageal and gastric cancer 1994–2003: population-based study". Endoscopy 38 (5): 503–7. doi:10.1055/s-2006-925124. PMID 16767587.
- Crane SJ, Locke GR, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ; Locke Gr; Harmsen; Zinsmeister; Romero; Talley (2008). "Survival Trends in Patients With Gastric and Esophageal Adenocarcinomas: A Population-Based Study". Mayo Clinic Proceedings 83 (10): 1087–94. doi:10.4065/83.10.1087. PMC 2597541. PMID 18828967.
- Heise K, Bertran E, Andia ME, Ferreccio C; Bertran; Andia; Ferreccio (2009). "Incidence and survival of stomach cancer in a high-risk population of Chile". World Journal of Gastroenterology 15 (15): 1854–62. doi:10.3748/wjg.15.1854. PMC 2670413. PMID 19370783.
- Ford, AC; Forman, D; Hunt, RH; Yuan, Y; Moayyedi, P (20 May 2014). "Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials.". BMJ (Clinical research ed.) 348: g3174. doi:10.1136/bmj.g3174. PMC 4027797. PMID 24846275.
- Roopma Wadhwa, Takashi Taketa, Kazuki Sudo, Mariela A. Blum, Jaffer A. Ajani; Taketa; Sudo; Blum; Ajani (2013). "Modern Oncological Approaches to Gastric Adenocarcinoma". Gastroenterology Clinics of North America 42 (2): 359–369. doi:10.1016/j.gtc.2013.01.011. PMID 23639645.
- Ke Chen, Xiao-Wu Xu, Ren-Chao Zhang, Yu Pan, Di Wu, Yi-Ping Mou; Xu; Zhang; Pan; Wu; Mou (2013). "Systematic review and meta-analysis of laparoscopy-assisted and open total gastrectomy for gastric cancer". World J Gastroenterol 19 (32): 5365–76. doi:10.3748/wjg.v19.i32.5365. PMC 3752573. PMID 23983442.
- Jennifer L. Pretz, Jennifer Y. Wo, Harvey J. Mamon, Lisa A. Kachnic, Theodore S. Hong; Wo; Mamon; Kachnic; Hong (2011). "Chemoradiation Therapy: Localized Esophageal, Gastric, and Pancreatic Cancer". Surgical oncology clinics of North America 22 (3): 511–524. doi:10.1016/j.soc.2013.02.005. PMID 23622077.
- Judith Meza-Junco, Heather-Jane Au, Michael B Sawyer; Au; Sawyer (2011). "Critical appraisal of trastuzumab in treatment of advanced stomach cancer". Cancer Management and Research 2011 (3): 57–64. doi:10.2147/CMAR.S12698. PMC 3085240. PMID 21556317.
- Sun, J; Song, Y; Wang, Z; Chen, X; Gao, P; Xu, Y; Zhou, B; Xu, H (December 2013). "Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis." (PDF). BMC cancer 13: 577. doi:10.1186/1471-2407-13-577. PMID 24304886.
- Scartozzi M, Galizia E, Verdecchia L, Berardi R, Antognoli S, Chiorrini S, Cascinu S; Galizia; Verdecchia; Berardi; Antognoli; Chiorrini; Cascinu (2007). "Chemotherapy for advanced gastric cancer: across the years for a standard of care". Expert Opinion on Pharmacotherapy 8 (6): 797–808. doi:10.1517/146565126.96.36.1997. PMID 17425475.
- Cabebe, EC; Mehta, VK; Fisher, G, Jr (21 January 2014). Talavera, F; Movsas, M; McKenna, R; Harris, JE, ed. "Gastric Cancer". Medscape Reference. WebMD. Retrieved 4 April 2014.
- "WHO Disease and injury country estimates". World Health Organization. 2009. Retrieved Nov 11, 2009.
- Parkin DM, Bray F, Ferlay J, Pisani P; Bray; Ferlay; Pisani (2005). "Global Cancer Statistics, 2002". CA: A Cancer Journal for Clinicians 55 (2): 74–108. doi:10.3322/canjclin.55.2.74. PMID 15761078.
- "Are the number of cancer cases increasing or decreasing in the world?". WHO Online Q&A. WHO. 1 April 2008. Retrieved 2009-05-11.
- World Cancer Report 2014. International Agency for Research on Cancer, World Health Organization. 2014. ISBN 978-92-832-0432-9.
- Lozano, R; Naghavi, M; Foreman, K; Lim, S; Shibuya, K; Aboyans, V; Abraham, J; Adair, T; Aggarwal, R; Ahn, SY; Alvarado, M; Anderson, HR; Anderson, LM; Andrews, KG; Atkinson, C; Baddour, LM; Barker-Collo, S; Bartels, DH; Bell, ML; Benjamin, EJ; Bennett, D; Bhalla, K; Bikbov, B; Bin Abdulhak, A; Birbeck, G; Blyth, F; Bolliger, I; Boufous, S; Bucello, C et al. (15 December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604.
- "PRESS RELEASE N° 224 Global battle against cancer won’t be won with treatment alone Effective prevention measures urgently needed to prevent cancer crisis". World Health Organization. 3 February 2014. Retrieved 14 March 2014.
- "Gastric Cancer in Young Adults". Revista Brasileira de Cancerologia 46 (3). Jul 2000.
- "Health profile: United States". Le Duc Media. Retrieved 13 March 2014.
- "Health profile: China". Le Duc Media. Retrieved 13 March 2014.
- "Health profile: Maldives". Le Duc Media. Retrieved 13 March 2014.
- "Stomach cancer statistics". Cancer Research UK. Retrieved 28 October 2014.
- Asombang Akwi W, Rahman Rubayat, Ibdah Jamal A (2014). "Gastric cancer in Africa: Current management and outcomes". World Journal of Gastroenterology 20: 3875–79. doi:10.3748/wjg.v20.i14.3875.
- Louw J. A., Kidd M. S. G., Kummer A. F., Taylor K., Kotze U., and Hanslo D. (November 2001). "The relationship between helicobacter pylori infection, the virulence genotypes of the infecting strain and gastric cancer in the African setting". Helicobacter 6 (4): 268–73.
- Withrow SJ, MacEwen EG, ed. (2001). Small Animal Clinical Oncology (3rd ed.). W.B. Saunders.
|Wikimedia Commons has media related to Stomach cancer.|